VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00436501 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

58

Enrollment

NIH

Sponsor class

Conditions

Fallopian Tube Cancer
Malignant Tumor of Peritoneum
Recurrent Ovarian Epithelial Cancer

Interventions

DRUG: docetaxel
BIOLOGICAL: ziv-aflibercept
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)